Precigen (PGEN) stock experienced a significant downturn, plummeting 5.28% in the last 24 hours of trading on Tuesday. The sharp decline comes in the wake of a crucial announcement that has sparked investor concern.

The biotech company filed to sell 143.81 million shares of common stock for holders, as reported in a regulatory filing. This substantial offering represents a significant portion of Precigen's outstanding shares, raising concerns about potential stock dilution among investors.

Stock dilution occurs when a company issues new shares, effectively reducing the ownership percentage of existing shareholders. This move often leads to a decrease in stock price as the market adjusts to the increased supply of shares. The market's immediate reaction to Precigen's filing suggests that investors are wary of the potential impact on their holdings.

As the biotechnology sector continues to face challenges, including regulatory hurdles and the need for substantial capital to fund research and development, companies like Precigen may resort to share offerings to raise funds. However, such actions can sometimes come at the cost of short-term stock performance, as evidenced by today's market reaction.